Cargando…

High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients

OBJECTIVE: Immediate early response 5 (IER5) plays a core role in cell cycle and response to irradiation. However, its role in glioma remains unclear. We aimed to evaluate its prognostic significance in glioma based on The Cancer Genome Atlas data resource. METHODS: The Kruskal–Wallis test, Wilcoxon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zijun, Wang, Dan, Zeng, Fanxin, Zhang, Yanrong, Zhu, Guannan, Ma, Yiqi, Song, Bin, Lui, Su, Wu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248409/
https://www.ncbi.nlm.nih.gov/pubmed/34222249
http://dx.doi.org/10.3389/fcell.2021.679684
_version_ 1783716717819592704
author Wu, Zijun
Wang, Dan
Zeng, Fanxin
Zhang, Yanrong
Zhu, Guannan
Ma, Yiqi
Song, Bin
Lui, Su
Wu, Min
author_facet Wu, Zijun
Wang, Dan
Zeng, Fanxin
Zhang, Yanrong
Zhu, Guannan
Ma, Yiqi
Song, Bin
Lui, Su
Wu, Min
author_sort Wu, Zijun
collection PubMed
description OBJECTIVE: Immediate early response 5 (IER5) plays a core role in cell cycle and response to irradiation. However, its role in glioma remains unclear. We aimed to evaluate its prognostic significance in glioma based on The Cancer Genome Atlas data resource. METHODS: The Kruskal–Wallis test, Wilcoxon signed-rank test, and logistic regression were employed to explore the relationship between IER5 expression and clinicopathological features. Kaplan–Meier and Cox regression analyses were implemented to investigate the relationship of IER5 with prognosis. A nomogram to estimate the impact of IER5 on prognosis was created based on the Cox multivariate data. We performed gene set enrichment analysis (GSEA) to determine the key signaling cascades associated with IER5. Immunohistochemistry was performed to examine IER5 expression in a tissue microarray (TMA) of glioma samples. RESULTS: Immediate early response 5 gene expression was elevated in glioma patients. The level of IER5 was significantly correlated with WHO grade [OR = 6.71 (4.34–10.68) for G4 vs. G2 and G3], IDH (isocitrate dehydrogenase enzyme) status [OR = 13.35 (8.92–20.46) for wild-type (WT) vs. mutated (Mut)], epidermal growth factor receptor status [OR = 8.42 (4.32–18.43) for Mut vs. WT], age [OR = 0.27 (0.18–0.41) for ≤ 60 years vs. >60 years], and histological type [OR = 7.13 (4.63–11.31] for glioblastoma vs. astrocytoma, oligoastrocytoma, and oligodendroglioma). Univariate analyses revealed that high IER5 expression was linked to short overall survival (OS) [hazard ratio (HR): 3.747; 95% confidence interval (CI): 2.847–4.933; and P < 0.001]. High IER5 expression was linked to poor OS in multivariate analyses (HR: 2.474; 95% CI: 1.552–3.943; and P < 0.001). TMA results showed that high IER5 protein levels were related to short OS (HR: 1.84; 95% CI: 1.10–3.07; and P = 0.021) and poor disease-specific survival (HR: 1.82; 95% CI: 1.09–3.04; and P = 0.023). GSEA showed that many tumor related pathways were enriched differentially in the IER5-high expression group. The C-index and calibration plots of the nomogram showed an effective estimation performance in glioma patients. CONCLUSION: Herein, we established that IER5 plays a critical role in glioma progression and prognosis, which might be an important biomarker for the prognosis of glioma patients.
format Online
Article
Text
id pubmed-8248409
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82484092021-07-02 High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients Wu, Zijun Wang, Dan Zeng, Fanxin Zhang, Yanrong Zhu, Guannan Ma, Yiqi Song, Bin Lui, Su Wu, Min Front Cell Dev Biol Cell and Developmental Biology OBJECTIVE: Immediate early response 5 (IER5) plays a core role in cell cycle and response to irradiation. However, its role in glioma remains unclear. We aimed to evaluate its prognostic significance in glioma based on The Cancer Genome Atlas data resource. METHODS: The Kruskal–Wallis test, Wilcoxon signed-rank test, and logistic regression were employed to explore the relationship between IER5 expression and clinicopathological features. Kaplan–Meier and Cox regression analyses were implemented to investigate the relationship of IER5 with prognosis. A nomogram to estimate the impact of IER5 on prognosis was created based on the Cox multivariate data. We performed gene set enrichment analysis (GSEA) to determine the key signaling cascades associated with IER5. Immunohistochemistry was performed to examine IER5 expression in a tissue microarray (TMA) of glioma samples. RESULTS: Immediate early response 5 gene expression was elevated in glioma patients. The level of IER5 was significantly correlated with WHO grade [OR = 6.71 (4.34–10.68) for G4 vs. G2 and G3], IDH (isocitrate dehydrogenase enzyme) status [OR = 13.35 (8.92–20.46) for wild-type (WT) vs. mutated (Mut)], epidermal growth factor receptor status [OR = 8.42 (4.32–18.43) for Mut vs. WT], age [OR = 0.27 (0.18–0.41) for ≤ 60 years vs. >60 years], and histological type [OR = 7.13 (4.63–11.31] for glioblastoma vs. astrocytoma, oligoastrocytoma, and oligodendroglioma). Univariate analyses revealed that high IER5 expression was linked to short overall survival (OS) [hazard ratio (HR): 3.747; 95% confidence interval (CI): 2.847–4.933; and P < 0.001]. High IER5 expression was linked to poor OS in multivariate analyses (HR: 2.474; 95% CI: 1.552–3.943; and P < 0.001). TMA results showed that high IER5 protein levels were related to short OS (HR: 1.84; 95% CI: 1.10–3.07; and P = 0.021) and poor disease-specific survival (HR: 1.82; 95% CI: 1.09–3.04; and P = 0.023). GSEA showed that many tumor related pathways were enriched differentially in the IER5-high expression group. The C-index and calibration plots of the nomogram showed an effective estimation performance in glioma patients. CONCLUSION: Herein, we established that IER5 plays a critical role in glioma progression and prognosis, which might be an important biomarker for the prognosis of glioma patients. Frontiers Media S.A. 2021-06-17 /pmc/articles/PMC8248409/ /pubmed/34222249 http://dx.doi.org/10.3389/fcell.2021.679684 Text en Copyright © 2021 Wu, Wang, Zeng, Zhang, Zhu, Ma, Song, Lui and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Wu, Zijun
Wang, Dan
Zeng, Fanxin
Zhang, Yanrong
Zhu, Guannan
Ma, Yiqi
Song, Bin
Lui, Su
Wu, Min
High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title_full High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title_fullStr High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title_full_unstemmed High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title_short High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients
title_sort high ier5 gene expression is associated with poor prognosis in glioma patients
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248409/
https://www.ncbi.nlm.nih.gov/pubmed/34222249
http://dx.doi.org/10.3389/fcell.2021.679684
work_keys_str_mv AT wuzijun highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT wangdan highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT zengfanxin highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT zhangyanrong highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT zhuguannan highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT mayiqi highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT songbin highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT luisu highier5geneexpressionisassociatedwithpoorprognosisingliomapatients
AT wumin highier5geneexpressionisassociatedwithpoorprognosisingliomapatients